Bioelectronics

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Retrieved on: 
星期一, 三月 25, 2024
Prevalence, Exercise, Gastrointestinal bleeding, Risk, GI, Sale, Nonsteroidal anti-inflammatory drug, Running, Veterinary medicine, Motion, OA, Chronic pain, Quality of life, Osteoarthritis, Arthritis, Dog, PROM, Aspirin, Cartilage, Bioelectronics, FDA, Animal, BIEL, Ibuprofen, Audit

Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Ninety-six percent of the treatment group showed either increased PROM or improved behavioral changes or both compared to 4% for the placebo group. Most changes occurred within the first 8 days of treatment.

Key Points: 
  • The study was published online by Veterinary Medicine & Science, and can be viewed here: https://doi.org/10.1002/vms3.1408
    A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint.
  • BioElectronics’ Model 088 device was secured near the cervical region of the dog’s spine.
  • Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs.
  • Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.

EnLiSense CCM Advances Validation of Real-Time IBD Inflammatory Biomarker Monitoring with Two Recent Peer-Reviewed Longitudinal Studies

Retrieved on: 
星期四, 二月 15, 2024
Hardware, Health Technology, Data Management, Other Health, Technology, Professional Services, Biometrics, Medical Devices, Genetics, Artificial Intelligence, Wearables, Mobile Technology, Biotechnology, Science, Data Analytics, Research, Health, Biosensor, Digital health, Ulcerative colitis, Senior, Doctor of Philosophy, Translation, Hasso Plattner Institute, Moses Austin, MD, Professor, Inflammation, Blood, IL-6, Quality of life, Bioelectronics, Gastrointestinal tract, Trial of the century, Scientific Reports, Management, University, Perspiration, CRP, Clinical, Inflammatory bowel disease, Patient, Biological engineering, Optimism, IBD, Conditional sentence, TNF, Endoscopy, National Institutes of Health, Medical imaging

Our innovative IBD Aware device offers the first solution for continuous, non-invasive monitoring of IBD through the power of sweat-sensing technology.

Key Points: 
  • Our innovative IBD Aware device offers the first solution for continuous, non-invasive monitoring of IBD through the power of sweat-sensing technology.
  • EnLiSense's journey reaches a significant milestone with over half a million human biomarker readings, underscoring the extensive validation of our technology.
  • These readings provide crucial data points, enhancing the precision and trustworthiness of inflammatory biomarker monitoring.
  • The studies involved measuring inflammation markers CRP, TNF-α, and IL-6 in subjects' blood and sweat continuously in subjects with and without IBD.

End of Year Message From the Chairman of the Board of BioElectronics

Retrieved on: 
星期五, 十二月 22, 2023
Thumb, Veterinary medicine, CIS, Research, FDA, Chronic pain, Phantom limb, Paper, Osteoarthritis, DTR, Stanford University, Dog, University, UCSD, Social media, Bioelectronics, BIEL, Growth, OTC, News

FREDERICK, MD, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corp. (OTC: BIEL) is pleased to provide this end of year message to investors, customers, suppliers and other partners.

Key Points: 
  • FREDERICK, MD, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corp. (OTC: BIEL) is pleased to provide this end of year message to investors, customers, suppliers and other partners.
  • All indications are that the results are very positive, but they are embargoed until they appear in press.
  • If this paper is published, we plan to start actively marketing our RecoveryRx line into the veterinary market.
  • On a more positive note, BioElectronics would like to extend Season Greetings to all its customers and loyal shareholders.

Salvia BioElectronics: First-Ever Patient Treated with Breakthrough Neuromodulation Solution for Severe Migraine and Cluster Headache in Australia

Retrieved on: 
星期三, 八月 23, 2023
Migraine, Anatomy, Clinical trial, Head, Cluster headache, Brain, Sunshine Coast, Bioelectronics, Patient, Hospital, Health, Headache, Medical device

NAMBOUR, Australia, Aug. 23, 2023 /PRNewswire/ -- In a remarkable medical milestone, an Australian patient at Nambour Selangor Private Hospital became the first-ever patient to receive Salvia BioElectronics' paper-thin neuromodulation solution for severe migraine and cluster headache.

Key Points: 
  • NAMBOUR, Australia, Aug. 23, 2023 /PRNewswire/ -- In a remarkable medical milestone, an Australian patient at Nambour Selangor Private Hospital became the first-ever patient to receive Salvia BioElectronics' paper-thin neuromodulation solution for severe migraine and cluster headache.
  • Dr. Paul Frank, the interventional pain specialist who performed the procedure, emphasised that this breakthrough "ushers in a new era of possibilities in headache treatment."
  • Recognizing this unmet need, Salvia BioElectronics was founded in 2017 with a clear mission: to restore the lives of people with severe headache.
  • The company focuses on developing flexible bioelectronic foils that can conform to the anatomy of the head, offering a promising neuromodulation solution.

Salvia BioElectronics: First-Ever Patient Treated with Breakthrough Neuromodulation Solution for Severe Migraine and Cluster Headache in Australia

Retrieved on: 
星期三, 八月 23, 2023
Migraine, Anatomy, Clinical trial, Head, Cluster headache, Brain, Sunshine Coast, Bioelectronics, Patient, Hospital, Health, Headache, Medical device

NAMBOUR, Australia, Aug. 23, 2023 /PRNewswire/ -- In a remarkable medical milestone, an Australian patient at Nambour Selangor Private Hospital became the first-ever patient to receive Salvia BioElectronics' paper-thin neuromodulation solution for severe migraine and cluster headache.

Key Points: 
  • NAMBOUR, Australia, Aug. 23, 2023 /PRNewswire/ -- In a remarkable medical milestone, an Australian patient at Nambour Selangor Private Hospital became the first-ever patient to receive Salvia BioElectronics' paper-thin neuromodulation solution for severe migraine and cluster headache.
  • Dr. Paul Frank, the interventional pain specialist who performed the procedure, emphasised that this breakthrough "ushers in a new era of possibilities in headache treatment."
  • Recognizing this unmet need, Salvia BioElectronics was founded in 2017 with a clear mission: to restore the lives of people with severe headache.
  • The company focuses on developing flexible bioelectronic foils that can conform to the anatomy of the head, offering a promising neuromodulation solution.

Non-invasive ultrasound stimulation of the spleen reduces inflammation in humans, new results from a clinical trial

Retrieved on: 
星期一, 四月 24, 2023
Research, Hospitals, Diabetes, Other Health, Radiology, Managed Care, Health, Science, Oncology, Infection, Human, Obesity, TNF, FUS, Feinstein Institutes for Medical Research, Vagus nerve, Arthritis, Inflammatory Bowel Diseases, Cancer, GE, DRS, Multimedia, Inflammation, Biomedical engineering, Doctor of Philosophy, MS, Neuroscience, Bioelectronics, Spleen, Patient, GE Research, Blood, Feinstein, Pulmonary hypertension, Credit, Molecular medicine, Medical research, Disease, Medical imaging, Medical device, Vaccine, MD

Results from human studies published in the journal Brain Stimulation point to the possibility of using bioelectronic medicine and neuromodulation to treat inflammatory diseases traditionally treated only with drugs.

Key Points: 
  • Results from human studies published in the journal Brain Stimulation point to the possibility of using bioelectronic medicine and neuromodulation to treat inflammatory diseases traditionally treated only with drugs.
  • Sangeeta Chavan (left) and Stavros Zanos (right) helped lead the new study which published in the journal Brain Stimulation.
  • In 2021, the Feinstein Institutes and GE Research team showed the anti-inflammatory effects of liver-focused ultrasound on obesity in preclinical models.
  • Chavan and Zanos, along with GE Research and other collaborators, showed the ability of ultrasound to reverse diabetes in preclinical studies.

Electromedical Technologies Announces Financial and Operational Highlights for the Three and Nine Months Ended September 30, 2022

Retrieved on: 
星期一, 十二月 5, 2022
Cloud, Stock dilution, Federal Food, Drug, and Cosmetic Act, Retirement, Negotiation, Pain, VNS, Sale, IDNA, Loss, Research, PNS, Q1, ALL, CES, Low-level laser therapy, FDA, Bioelectronics, Overalls, EMS, POD, Growth, University, Infinity, PEMF, Marketing, TENS, Renewable energy, Pharmaceutical industry, Medical imaging, Video game console, Risk management

SCOTTSDALE, Ariz., Dec. 5, 2022 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three and nine months ended September 30, 2022.

Key Points: 
  • Electromedical Technologies Announces Financial and Operational Highlights for the Three and Nine Months Ended September 30, 2022
    SCOTTSDALE, Ariz., Dec. 5, 2022 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three and nine months ended September 30, 2022.
  • Highlights for the three and nine months ended Sep 30, 2022
    Strong net sales during the quarter totaling approximately $280,000, beating both Q1 and Q2 2022 sales.
  • Net loss for the nine months ended Sep 30, 2022, of $2.64 million, a 60% improvement over net loss for the nine months ended Sep 30, 2021.
  • Approximately $900K in net financing used to expedite development of the new WellnessPro Infinity Flagship Device.

Electromedical Technologies Introduces the WellnessPro Infinity™

Retrieved on: 
星期二, 十一月 1, 2022
Cloud, Goal, IDNA, CES, Retirement, CEO, PEMF, Defence Bioengineering and Electromedical Laboratory, Pain, Loss, Opioid epidemic, Research, Terminology, POD, Low-level laser therapy, University, NEW, Opioid, Private Securities Litigation Reform Act, VNS, Bioelectronics, EMS, Company, FDA, PNS, Portal, Federal Food, Drug, and Cosmetic Act, Forward-looking statement, IF, OTCQB, ALL, Risk management

SCOTTSDALE, Ariz., Oct. 31, 2022 /PRNewswire/ -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is very excited to introduce its new next-generation flagship device, the WellnessPro Infinity™.

Key Points: 
  • SCOTTSDALE, Ariz., Oct. 31, 2022 /PRNewswire/ -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. ( OTCQB: EMED ) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is very excited to introduce its new next-generation flagship device, the WellnessPro Infinity.
  • "The WellnessPro Infinity will set an entirely new standard in the Bioelectronics marketplace" remarked Electromedical Founder and CEO, Matthew Wolfson.
  • The NEW WellnessPro Infinity device features:
    One compact device that encompasses ALL electrotherapy modalities.
  • Our goal is to go to market with the WellnessPro Infinity first, then shortly after releasing the POD upon FDA 510k clearance."

Feinstein Institutes’ fifth Bioelectronic Medicine Summit spotlights innovation, future of science

Retrieved on: 
星期四, 十月 13, 2022
Research, Hardware, Pharmaceutical, Technology, Medical Devices, Health Technology, Clinical Trials, Science, Neurology, Biotechnology, Other Technology, Health, Other Science, National Institutes of Health, LinkedIn, Biomedical engineering, Applied science, Disease, Medicine, Arthritis, Columbia, Science, Pulmonary hypertension, Time-invariant system, Machine learning, University of Pittsburgh, Immunity, Medical research, Neuroscience, Lists of diseases, DARPA, Research, Multimedia, Feinstein Institute for Medical Research, BioMed Central, Nervous system, Mental health, Institute, Bioelectronics, Knowledge, Cancer, University, R, Molecular medicine, Doctor of Philosophy, National, Garden, CEO, Summit, Autoimmunity, Behavioural sciences, Partnership, Genetics, Springer Nature, Northwell Health, Paralysis, Inflammatory bowel disease, Metabolism, Garden City Hotel, Credit, Â, Data science, Biomarker, Biochemistry, Pharmaceutical industry, Medical device, Medical imaging, Management, Engineering, MD

Some of the most influential international medical experts, researchers and scientific minds participated in the fifth Bioelectronic Medicine Summit, Bioelectronic Medicine: Todays Tools, Tomorrows Therapies , hosted by The Feinstein Institutes for Medical Research .

Key Points: 
  • Some of the most influential international medical experts, researchers and scientific minds participated in the fifth Bioelectronic Medicine Summit, Bioelectronic Medicine: Todays Tools, Tomorrows Therapies , hosted by The Feinstein Institutes for Medical Research .
  • View the full release here: https://www.businesswire.com/news/home/20221013005978/en/
    Dr. Kevin J. Tracey delivers a keynote address at the Bioelectronic Medicine Summit.
  • Anil Malhotra , MD, co-director of the Institute of Behavioral Science at the Feinstein Institutes, explained how bioelectronic medicine could help treat neuropsychiatric disorders.
  • The Feinstein Institutes, the global scientific home of bioelectronic medicine, continues to invest in bioelectronic medicine.

Feinstein Institutes Scientists Outline in Neuron Bioelectronic Medicine Advances, Future of Clinical Care

Retrieved on: 
星期一, 十月 10, 2022
Health, Neurology, Other Health, Clinical Trials, Research, Science, Biotechnology, LinkedIn, Biomedical engineering, Retina, Disease, Medicine, Rheumatoid arthritis, Inflammation, Electricity, Science, Pulmonary hypertension, Machine learning, Deep brain stimulation, Medical research, Neuroscience, Patient, Depression, Research, Multimedia, Feinstein Institute for Medical Research, Lists of diseases, Mental health, Institute, Bioelectronics, Cancer, Technology, Molecular medicine, Doctor of Philosophy, MD, DRS, Miniaturization, CEO, Â, Diabetes, Artificial intelligence, Autoimmunity, Genetics, Optogenetics, Northwell Health, Paralysis, Inflammatory bowel disease, Homeostasis, Credit, Vagus nerve, Algorithm, Pharmaceutical industry, Medical device, Neuron

View the full release here: https://www.businesswire.com/news/home/20221010005549/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221010005549/en/
    Valentin Pavlov, PhD, professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes, is one of the co-authors of the new article recently published in Neuron.
  • (Credit: Feinstein Institutes)
    The Feinstein Institutes is the global scientific home of bioelectronic medicine.
  • Investigators within the Institute of Bioelectronic Medicine at the Feinstein Institutes have studied the use of electricity to target nerves to control inflammation within the body for more than two decades.
  • Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine.